{"product_id":"gilead-swot-analysis","title":"Gilead Sciences SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGilead Sciences leverages a strong antiviral portfolio and robust R\u0026amp;D pipeline, but faces patent cliffs, pricing pressures, and fierce competition in oncology and antivirals.\u003c\/p\u003e\n\u003cp\u003eDiscover the full SWOT analysis for a research-backed, editable report and Excel matrix that reveals strategic opportunities, financial context, and risk mitigants tailored for investors and advisors—purchase now to plan with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant HIV Market Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead holds a commanding position in HIV care, driven by Biktarvy’s blockbuster sales—about $6.8 billion in 2024—and it captured over 70% of the treatment‑naive market as of late 2025, per company reporting.\u003c\/p\u003e\n\u003cp\u003eThis scale delivers a stable revenue stream financing R\u0026amp;D (Gilead’s 2024 R\u0026amp;D spend was $3.6 billion) and benefits from high clinical, regulatory, and patent barriers that limit smaller rivals’ entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Oncology Portfolio Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead has diversified revenue by rapidly scaling its oncology unit, led by Trodelvy (sacituzumab govitecan), which drove oncology sales to about $2.6 billion in 2024 and is projected to push oncology revenue past $4 billion by end-2025.\u003c\/p\u003e\n\u003cp\u003eTrodelvy, a TROP-2 antibody-drug conjugate, secured multiple FDA and EMA indications through 2024–25, materially boosting top-line growth and raising oncology share of total revenue to roughly 15% by 2025.\u003c\/p\u003e\n\u003cp\u003eThis shift cuts Gilead’s historical dependence on antivirals (HIV\/HCV), positioning the company as a credible oncology competitor and creating a second major revenue pillar. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading Cell Therapy Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThrough subsidiary Kite Pharma, Gilead leads cell therapy with CAR-Ts Yescarta and Tecartus, which generated combined 2024 revenue of about $1.9 billion; Kite reports median vein-to-vein turnaround times near 17 days, faster than many rivals. This manufacturing edge raises patient throughput and supports better outcomes in hematologic malignancies, helping market share gains as Kite advances approvals into earlier therapy lines in 2023–2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Position and Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead generates large free cash flow from established antivirals—$7.8B operating cash flow and $4.1B free cash flow in 2025—funding deal-making and R\u0026amp;D without equity dilution.\u003c\/p\u003e\n\u003cp\u003eAt end-2025 Gilead held about $18.2B cash and marketable securities with $11.5B net debt, keeping credit metrics solid and enabling steady dividends and buybacks.\u003c\/p\u003e\n\u003cp\u003eThat balance-sheet strength lets Gilead pursue strategic acquisitions while maintaining investment-grade standing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$4.1B free cash flow (2025)\u003c\/li\u003e\n\u003cli\u003e$18.2B cash \u0026amp; securities (Dec 31, 2025)\u003c\/li\u003e\n\u003cli\u003e$11.5B net debt (Dec 31, 2025)\u003c\/li\u003e\n\u003cli\u003eConsistent dividends + buybacks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovation in Long-Acting Injectables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead’s long-acting injectables strengthen product lifecycle management; lenacapavir, approved by FDA in December 2022 for heavily treatment-experienced HIV, expanded to a 6-month dosing option and drove commercial uptake with estimated 2025 sales of lenacapavir-related franchise ~USD 450–600M per company guidance ranges.\u003c\/p\u003e\n\u003cp\u003eLess frequent dosing improves adherence and brand loyalty versus daily oral regimens, raising switching costs and forming a defensive moat against competitors’ oral options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFirst-in-class capsid inhibitor: lenacapavir (approved Dec 2022)\u003c\/li\u003e\n\u003cli\u003e6-month dosing increases adherence; 2025 est. sales ~USD 450–600M\u003c\/li\u003e\n\u003cli\u003eEnhances lifecycle management and competitor defensibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead: HIV dominance, oncology ramp, CAR‑T scale and $4.1B FCF fueling R\u0026amp;D\/M\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead’s strengths: market leadership in HIV (Biktarvy ~$6.8B 2024; \u0026gt;70% treatment‑naive share by late‑2025), growing oncology (Trodelvy ~$2.6B 2024; oncology \u0026gt;15% revenue by 2025), CAR‑T scale (Kite combined ~$1.9B 2024; ~17‑day vein‑to‑vein), strong cash flow ($4.1B FCF 2025) and liquid balance sheet ($18.2B cash, $11.5B net debt end‑2025) enabling R\u0026amp;D and M\u0026amp;A.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$6.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrodelvy sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$2.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKite revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF (2025)\u003c\/td\u003e\n\u003ctd\u003e$4.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (Dec‑31‑2025)\u003c\/td\u003e\n\u003ctd\u003e$18.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (Dec‑31‑2025)\u003c\/td\u003e\n\u003ctd\u003e$11.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Gilead Sciences, outlining its core strengths and weaknesses while mapping growth opportunities and external threats shaping the company’s strategic direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Gilead Sciences' strengths, weaknesses, opportunities, and threats in a compact SWOT matrix for rapid strategic alignment and executive briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Revenue Concentration in HIV\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite diversification moves, Gilead reported ~45% of 2024 revenue from its HIV franchise (about $13.5B of $30B total), leaving the company exposed if HIV faces pricing pressure, regulatory shifts, or a breakthrough cure.\u003c\/p\u003e\n\u003cp\u003eInvestors worry long-term growth could stall if market saturation occurs; a manufacturing or supply-chain disruption for core HIV drugs would hit margins and cash flow disproportionately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStagnant Growth in HCV Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthe hepatitis c virus portfolio once gilead sciences primary growth engine has moved into a mature phase with global hcv revenues falling from about in to roughly reflecting shrinking addressable market as more patients are cured. prevalence declines value erodes steadily turning the segment steady but non-explosive profit source. this trend forces rely on oncology and hiv b divisions hit corporate targets. if other units underperform overall revenue will slow significantly.\u003e\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecent Clinical and R\u0026amp;D Setbacks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead has seen several late-stage failures and regulatory setbacks as it expands beyond antivirals; in 2023–2025 multiple inflammation and oncology candidates missed primary endpoints, prompting roughly $1.2 billion in R\u0026amp;D write-downs and a 15% cut in projected pipeline-driven revenue, which underlines drug-development risk and has weakened investor confidence and scrutiny of R\u0026amp;D efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Integration Complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe aggressive acquisition push since 2019, including the $21 billion acquisition of Kite Therapeutics in 2021 and other deals totaling ~ $30–35B, has strained integration of cultures and R\u0026amp;D platforms, raising operational complexity for Gilead Sciences.\u003c\/p\u003e\n\u003cp\u003eHarmonizing global teams and legacy data systems demands senior management time and capex; integration inefficiencies contributed to higher SG\u0026amp;A and R\u0026amp;D run-rates and delayed oncology launches in 2023–2024.\u003c\/p\u003e\n\u003cp\u003eEnsuring acquired assets meet projected NPV and revenue targets remains a recurring executive risk, with realized synergies often trailing forecasts by 12–24 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh deal spend: ~$30–35B since 2019\u003c\/li\u003e\n\u003cli\u003eSynergy lag: 12–24 months\u003c\/li\u003e\n\u003cli\u003eIntegration drives higher SG\u0026amp;A\/R\u0026amp;D run-rates\u003c\/li\u003e\n\u003cli\u003eRisk to projected NPV and launch timelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegal and Intellectual Property Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead faces frequent, complex litigation over patents and government pricing. As of late 2025, disputes around key HIV drugs (notably remnant patent claims tied to Biktarvy components) add forecasting uncertainty and could invite earlier generic entry.\u003c\/p\u003e\n\u003cp\u003eUnfavorable rulings may force significant settlements or accelerated revenue loss; legal fees and reserves reduced operating cash—Gilead reported $1.1bn in litigation charges in FY2024 and set $2.3bn contingency for 2025 risks.\u003c\/p\u003e\n\u003cp\u003eThese cases consume management time, distract R\u0026amp;D strategy, and create ongoing balance-sheet and cash-flow strain.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFrequent patent and pricing litigation\u003c\/li\u003e\n\u003cli\u003eLate-2025 HIV-IP disputes raise uncertainty\u003c\/li\u003e\n\u003cli\u003eRisk of earlier generics or large settlements\u003c\/li\u003e\n\u003cli\u003e$1.1bn legal charges (FY2024); $2.3bn 2025 reserves\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy HIV reliance, costly M\u0026amp;A \u0026amp; legal risks threaten growth and execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy HIV reliance (~45% of 2024 revenue; ~$13.5B of $30B), mature HCV sales down to ~$2.2B (2024), $30–35B M\u0026amp;A since 2019 with 12–24m synergy lag, ~$1.2B R\u0026amp;D write-downs (2023–25), $1.1B legal charges (FY2024) and $2.3B reserves (2025) raise execution, pipeline, and litigation risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV share (2024)\u003c\/td\u003e\n\u003ctd\u003e45% (~$13.5B)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCV revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$2.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A spend (since 2019)\u003c\/td\u003e\n\u003ctd\u003e$30–35B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D write-downs (2023–25)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal charges (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal reserves (2025)\u003c\/td\u003e\n\u003ctd\u003e$2.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eGilead Sciences SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752473309561,"sku":"gilead-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/gilead-swot-analysis.png?v=1772241431","url":"https:\/\/growthsharematrix.com\/products\/gilead-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}